Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vahle, J. L.
Right arrow Articles by Sato, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vahle, J. L.
Right arrow Articles by Sato, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 32, No. 4, 426-438 (2004)
DOI: 10.1080/01926230490462138

Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose

John L. Vahle

Lilly Research Laboratories, Greenfield, Indiana, jvahle{at}lilly.com

Gerald G. Long

Lilly Research Laboratories, Greenfield, Indiana

George Sandusky

Lilly Research Laboratories, Greenfield, Indiana

Michael Westmore

Lilly Research Laboratories, Greenfield, Indiana

Yanfei Linda Ma

Lilly Research Laboratories, Greenfield, Indiana

Masahiko Sato

Lilly Research Laboratories, Greenfield, Indiana

A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions. Treatment groups consisted of different combinations of dose (0, 5, or 30 µg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age). The primary endpoints were the incidence of bone neoplasms and effects on bone mass and structure as evaluated by quantitative computed tomography and histomorphometery. Significant increases in the incidence of bone tumors (osteoma, osteoblastoma, and osteosarcoma) occurred in rats treated with 30 µg/kg for 20 or 24 months. No neoplasms were found when the 5 µg/kg treatment was initiated at 6 months of age and continued for either 6 or 20 months (up to 70% of life span). This treatment regimen defined a "no-effect" dose for neoplasm formation that nevertheless resulted in substantial increases in bone mass. These results demonstrate that treatment duration and administered dose are the most important factors in the teriparatide-induced bone tumors in rats.

Key Words: PTH • teriparatide • rat • bone • neoplasms • osteoporosis treatment • osteosarcoma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 IBMS BoneKEyHome page
E. F. Nemeth
Anabolic Therapy for Osteoporosis: Calcilytics
IBMS BoneKEy, June 1, 2008; 5(6): 196 - 208.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
L. Gehrig, J. Lane, and M. I. O'Connor
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374.
[Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. L. Vahle, M. Sato, and G. G. Long
Letter to the Editor
Toxicol Pathol, December 1, 2007; 35(7): 1045 - 1046.
[Full Text] [PDF]